Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Completed · Phase 2

Conditions studied: Advanced Cutaneous Squamous Cell Carcinoma

In brief

The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.

Key facts

Study ID
NCT02760498
Run by
Regeneron Pharmaceuticals
People needed
432
Starts
2016-04-07
Expected to finish
2023-10-18
Last updated by the study team
2025-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.